Evolus (NASDAQ:EOLS) Inc CEO David Moatazedi joined Steve Darling from Proactive to share news the company has released data from a Phase II clinical study evaluating an "extra-strength" formulation for extended duration of its flagship product Jeuveau. Moatazedi telling Proactive the data seemed to show the extra-strength formulation of Jeuveau achieved a duration profile of 6 months or 26 weeks. Jeuveau is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults under the age of 65.
Evolus presents data from Phase 2 clinical study evaluating an extra-strength formulation of Jeuveau
